Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MACROPHAGES IN T1D

Financiado

Cerrado

Functional profiling and therapeutic tolerization of macrophages in type 1 diabe...

Functional profiling and therapeutic tolerization of macrophages in type 1 diabetes Type 1 diabetes (T1D) is a chronic condition that results from the specific destruction of pancreatic beta cells by the immune system. As a consequence, affected individuals can no longer regulate their blood sugar levels and beco... ver más

29/02/2016

UGent

100K€

Presupuesto del proyecto: 100K€

Líder del proyecto

UNIVERSITEIT GENT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-02-29 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UGent

0.00€ | Lider

Proyectos interesantes

PID2020-117569RA-I00

Medical Technol...

Immunology

158K€ Cerrado

MIELT1D

Medical Technol...

Immunology

119K€ Cerrado

SAF2010-21977

Medical Technol...

Immunology

18K€ Cerrado

SAF2012-35344

Medical Technol...

Immunology

291K€ Cerrado

EE-ASI

Medical Technol...

Immunology

8M€ Cerrado

HONEYDIAB-8

Medical Technol...

Immunology

183K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

UNIVERSITEIT GENT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 100K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Type 1 diabetes (T1D) is a chronic condition that results from the specific destruction of pancreatic beta cells by the immune system. As a consequence, affected individuals can no longer regulate their blood sugar levels and become dependent on glucose monitoring and insulin injections. Despite careful disease management, serious neuronal and vascular long-term complications can often not be avoided. This debilitating disease is an important and growing public health concern in Europe: it is predicted that by 2020 approximately 24.400 individuals will be diagnosed with T1D annually. It is thought that T cells are the principal effector subset that drives beta cell decay within the islets of Langerhans. Inflammatory islet lesions (‘insulitis’) are predominantly populated by T cells and T cell species reactive against pancreatic islet antigens can be found in the blood around disease onset. The importance of innate immunity and in particular macrophages has historically attracted a minor degree of attention. Nevertheless, macrophages are abundantly represented within islet infiltrates from patients and are required for disease manifestation in animal models. Recent evidence from clinical trials has exposed the failure of strategies for inducing peripheral T cell tolerance, most recently with anti-CD3 antibody therapy. While genetically defined thymic escape and consequent T cell autoimmunity may be very important in type 1 diabetes, we hypothesize that T cell-mediated recruitment and activation of macrophages represents a secondary yet significant pathological pathway. The research outlined in this application is designed to determine the functional phenotype of islet-infiltrating macrophages around diagnosis, their role in antigen shuttling to the pancreatic lymph nodes and their capacity to adopt a tolerogenic role upon treatment.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores